Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Akt

Protein kinase B (PKB), also known as Akt, is a serine/threonine-specific protein kinase that plays a key role in multiple cellular processes such as glucose metabolism, apoptosis, cell proliferation, transcription, and cell migration.

  • AKT Kinase Inhibitor
    T10276842148-40-7In house
    AKT Kinase Inhibitor is an Akt inhibitor with antitumor activity that selectively inhibits cell proliferation in a dose-dependent manner.
    • $138
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
  • Ipatasertib
    T62521001264-89-6
    Ipatasertib (GDC-0068) (GDC-0068), a highly specific pan-Akt inhibitor, targets Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM, respectively.
    • $39
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • MK-2206 dihydrochloride
    T19521032350-13-2
    MK-2206 dihydrochloride (MK-2206 2HCl) is a variant Akt inhibitor that inhibits Akt1, Akt2, and Akt3 (IC50=8/12/65 nM) with orally active, highly potent and selective potency. MK-2206 dihydrochloride exhibits antitumor activity.
    • $30
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • Uprosertib
    T68491047634-65-0
    Uprosertib (GSK2141795) (GSK2141795) is a selective, ATP-competitive, and orally bioavailable Akt inhibitor with IC50 of 180 nM, 328 nM, and 38 nM for Akt 1, 2 and 3, respectively. Phase 2.
    • $39
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • Capivasertib
    T19201143532-39-1
    Capivasertib (AZD5363) is a broad-spectrum AKT inhibitor with inhibitory activity against Akt1, Akt2, and Akt3 (IC50=3/7/7 nM) with oral activity. Capivasertib has antitumor activity for the treatment of breast cancer.
    • $34
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • Oridonin
    T279028957-04-2
    Oridonin (NSC-250682) is a diterpenoid isolated from Rabdosia rubescens with anti-tumor, anti-bacterial and anti-inflammatory effects. It acts as an inhibitor of AKT, with IC50s of 8.4 and 8.9 μM for AKT1 and AKT2.
    • $45
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Sophocarpine monohydrate
    T2746145572-44-7
    Sophocarpine monohydrate, a major ingredient of Sophora alopecuroides, has a wide range of pharmacological effects.
    • $50
    In Stock
    Size
    QTY
  • Farrerol
    T6S052524211-30-1
    1. Farrerol has antioxidative activity.2. Farrerol modulates TAP and BNBD5 gene expression in mammary gland, enhances bMEC defense against S. aureus infection and could be useful in protection against bovine mastitis. 3. Farrerol inactivates KEAP-1 or act
    • $110
    In Stock
    Size
    QTY
  • Methyl-Hesperidin
    T022811013-97-1
    Methyl Hesperidin, a flavanone glycoside (flavonoid) (C28H34O15), is abundant in citrus fruits. Its aglycone form is called hesperetin.
    • $50
    In Stock
    Size
    QTY
  • Artemisinin
    T039263968-64-9
    Artemisinin (Qinghaosu) is an ancient Chinese herbal therapy for malarial fevers which has been recently found to have potent activity against many forms of malarial organisms, including chloroquine-resistant Plasmodium falciparum.
    • $58
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Glaucocalyxin A
    T4S049879498-31-0
    1. Glaucocalyxin A (Leukamenin F)-SBE-β-CD could be useful with a better solubility and sustained function in drug delivery. 2. Glaucocalyxin A activates caspase-3, decreases BAD phosphorylation, and reduces the expression of X-linked inhibitor of apoptosis protein. 3. Glaucocalyxin A inhibits Akt phosphorylation, suppresses proliferation, and promotes apoptosis in a dose-dependent manner, but not in normal glial cells. 4. Glaucocalyxin A inhibits collagen-stimulated tyrosine phosphorylation of Syk, LAT, and phospholipase Cγ2, the signaling events in collagen receptor GPⅥ pathway. 5. Glaucocalyxin A could potentially be developed as an antiplatelet and antithrombotic agent, can inhibit platelet p-selectin secretion and integrin activation by convulxin, is a GPVI selective ligand.
    • $100
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • 2,3-Butanediol
    T19094513-85-9
    2,3-Butanediol is a biotransformed butanediol derived from natural resources.
    • $40
    In Stock
    Size
    QTY
  • AKT Kinase Inhibitor HCl
    T10276L In house
    AKT Kinase Inhibitor HCl is an Akt inhibitor with antitumor activity.
    • $138
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • BI-69A11
    T251501233322-09-2
    BI-69A11 ((E)-3-(1H-Benzo[d]imidazol-2-yl)-1-(6-chloro-2-hydroxy-4-phenylquinolin-3-yl)prop-2-en-1-one) is a dual AKT and NFkB pathway inhibitor. It enhances the susceptibility of colon cancer cells to mda-7/IL-24-induced growth inhibition by targeting Akt.
    • $38
    In Stock
    Size
    QTY
  • SKLB-163
    T261931255099-06-9In house
    SKLB-163 acts by downregulating RhoGDI, activating JNK-1 signaling pathway and caspase-3, and reducing phosphorylated Akt and p44/42 MAPK.
    • $137
    In Stock
    Size
    QTY
  • A-674563 2HCl(552325-73-2(fb-2hcl))
    T6139L
    A-674563 2HCl is an Akt1 inhibitor with Ki of 11 nM, modest potent to PKA and >30-fold selective for Akt1 over PKC.
    • $78
    In Stock
    Size
    QTY
  • Triciribine phosphate
    T1969961966-08-3In house
    Triciribine phosphate (VD 002) is a highly selective AKT inhibitor that induces cell cycle arrest and cysteinyl asparagin-dependent apoptosis, inhibits neovascularization, and can be used in the study of leukemia.
    • $293
    In Stock
    Size
    QTY
  • Lenaldekar
    T24398418800-15-4
    Lenaldekar (LDK) inhibits T-cell expansion and autoimmune encephalomyelitis. Lenaldekar causes dephosphorylation of members of the PI3 kinase/AKT/mTOR pathway and delays sensitive cells in late mitosis.
    • $148
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • A-674563 HCl (552325-73-2(free base))
    T44442070009-66-2
    A-674563 is an orally available, ATP-competitive, and reversible inhibitor of Akt (Ki: 11 nM for Akt1) [1]. It exhibits inhibitory activity against PKA and Cdk2 (IC50: 16/46 nM) but is 10- to >1, 800-fold selective for Akt1 versus additional kinases in th
    • $77
    In Stock
    Size
    QTY
  • MBM-55S
    T119612083624-07-9In house
    MBM-55S is an effective inhibitor of Nek2 with an IC50 of 1 nM. MBM-55S indecus cell cycle arrest and apoptosis thereby inhibiting the proliferation of cancer cells. MBM-55S shows antitumor activities.
    • $195
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • AKT-I-1
    T25017473382-39-7
    AKT-I-1 is a selective and reversible inhibitor of Akt1.
    • $233
    In Stock
    Size
    QTY
  • Akt-I-1,2
    T23695473382-50-2
    Akt-I-1,2 is a selective inhibitor of Akt1 and Akt2.
    • $232
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Akt3 degrader 1
    T749822836342-69-7In house
    Akt3 degrader 1 is a specific Akt3 degrader with anticancer and antiproliferative activity that inhibits tumor growth in mice.Akt3 degrader 1 is used in the study of non-small cell lung cancer and pancreatic cancer.
    • $195
    In Stock
    Size
    QTY
  • MKC-1
    T9831125313-92-0In house
    MKC-1 (Ro-31-7453) is an orally bioavailable, small-molecule, bisindolylmaleimide cell cycle inhibitor with potential antineoplastic activity. MKC-1 and its metabolites inhibit tubulin polymerization, blocking the formation of the mitotic spindle, which may result in
    • $52
    In Stock
    Size
    QTY
  • Protectin D1
    T37379660430-03-5In house
    Protectin D1 (Neuroprotectin D1) is a neuroprotectin produced by neuronal cells and is a potential cardioprotective agent.Protectin D1 attenuates myocardial ischemia/reperfusion injury and inhibits imiquimod-induced psoriasis-like skin inflammation by modulating the PI3K/AKT signaling pathway.
    • $245
    In Stock
    Size
    QTY
  • Cenisertib
    T14925871357-89-0In house
    Cenisertib is A potent ATP-competitive multi-kinase inhibitor, showing inhibitory effects on the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5, FLT3, as well as kinase inhibitors of FER and its homolog. Cenisertib inhibits the growth of tumor mast cells (MCS) by inhibiting the activity of several different molecular targets. Cenisertib also inhibits tumor growth in pancreatic, breast, colon, ovarian and lung cancer and leukemia in xenograft models.
    • $987
    Backorder
    Size
    QTY
    TargetMol | Inhibitor Sale
  • PI3K/Akt/mTOR-IN-2
    T605642757804-89-8In house
    PI3K/Akt/mTOR-IN-2 is a potent PI3K/AKT/mTOR inhibitor.PI3K/Akt/mTOR-IN-2 has anticancer effects and is selective for MDA-MB-231 cells with an IC50 of 2.29 μM.PI3K/Akt/mTOR-IN-2 exhibits anticancer activity and induces cycle arrest and apoptosis in cancer cells. PI3K/Akt/mTOR-IN-2 has anticancer activity and can induce cycle arrest and apoptosis in cancer cells.
    • $33
    In Stock
    Size
    QTY
  • K-80003
    T117341292821-90-9In house
    K-80003(TX-803) is a potent retinol-like X-receptor-alpha regulator that inhibits TRxrα-dependent Akt activation and tumor cell growth.
    • $45
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • ZINC00640089
    T72968667880-11-7In house
    ZINC00640089 is a selective lipid carrier protein-2 (LCN2) inhibitor. ZINC00640089 inhibited cell proliferation and cell viability, and reduced AKT phosphorylation in SUM149 cells. ZINC00640089 can be used to study inflammatory breast cancer (IBC).
    • $60
    In Stock
    Size
    QTY
  • 3CAI
    T1403428755-03-5In house
    3CAI is a potent and specific AKT1 and AKT2 inhibitor which showed significant inhibition of AKT in an in vitro kinase assay and suppressed expression of AKT direct downstream targets such as mTOR and GSK3β as well as induced growth inhibition and apoptosis in colon cancer cells.
    • $50
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Ipatasertib dihydrochloride
    T153741396257-94-5In house
    Ipatasertib dihydrochloride (GDC-0068 dihydrochloride) is a highly selective and ATP-competitive inhibitor of pan-Akt (IC50s: 5, 18 and 8 nM for Akt1, Akt2 and Akt3, respectively).
    • $39
    In Stock
    Size
    QTY
  • Lupeol
    T2895545-47-1
    Lupeol (Monogynol B) is a novel androgen receptor inhibitor with anti-inflammatory and antioxidant activity.
    • $30
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Ethyl gallate
    T3729831-61-8
    Ethyl gallate (gallic acid ethyl ester) obviously decreases cell proliferation in MDA-MB-231 and MCF-7 cells in a dose- and time-dependent manner, exhibits cytotoxicity in a dose-dependent manner. Ethyl gallate can inhibit the abilities of invasion of breast cancer in vitro by inhibiting the mRNA levels of MMP-9/MMP-2, phosphorylation of Akt and protein expression of NF-κB and inhibits hydrogen peroxide signaling, may represent an alternative class of vasopressors for use in septic shock. Also, Ethyl gallate suppresses proliferation and invasion in human breast cancer cells by modulating the PI3K/Akt pathway, which may contribute to inhibiting their downstream targets such as NF-κB p-65, Bcl-2/Bax, and mRNA levels of MMP-2 and MMP-9 in breast cancer cells, could be used as potential antioxidants with safe therapeutic application in cancer chemotherapy.
    • $42
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Scutellarin
    T278927740-01-8
    Scutellarin (Scutellarein-7-glucuronide), an active flavone isolated from Scutellaria baicalensis, can inhibit RANKL-mediated MAPK and NF-κB signaling pathway in osteoclasts, and down-regulate the STAT3/Girdin/Akt signaling in HCC cells.
    • $45
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • (Z)-Guggulsterone
    T1728039025-23-5
    (Z)-Guggulsterone inhibits the growth of human prostate cancer cells by causing apoptosis. Z-guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–Akt signaling axis.
    • $91
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Honokiol
    T300135354-74-6
    Honokiol (NSC-293100) is the active principle of magnolia extract. It inhibits the activation of Akt and enhances the phosphorylation of ERK1/ERK2.
    • $50
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Afuresertib
    T19111047644-62-1
    Afuresertib (GSK2110183) is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity.
    • $33
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • PF-04691502
    T62511013101-36-4
    PF-04691502 is a potent and selective inhibitor of PI3K and mTOR kinases with antitumor activity.
    • $30
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Deguelin
    T6817522-17-8
    Deguelin ((-)-Deguelin) is a PI3K/AKT Inhibitor, which is a natural product isolated from plants in the Mundulea sericea family.
    • $44
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • 5α-Hydroxycostic acid
    TN3139132185-83-2
    5alpha-Hydroxycostic acid possesses anti-angiogenic ability by interfering the VEGF- and Ang2-related pathways, and it may be a good drug candidate.
    • $162
    Backorder
    Size
    QTY
    TargetMol | Inhibitor Sale
    TargetMol | Citations Cited
  • AKT inhibitor VIII
    T3346612847-09-3
    AKT inhibitor VIII (AKTi-1/2) is a highly specific Akt1/2 inhibitor (IC50: 58/210 nM). The selectivity for Akt1 is higher about 36-fold than Akt3.
    • $44
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • SC79
    T2274305834-79-1
    SC79 is an AKT agonist with specificity and blood-brain barrier permeability. SC79 specifically binds to the PH domain of AKT, activates cytoplasmic AKT, and inhibits AKT membrane translocation. SC79 has neuroprotective activity.
    • $52
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • GSK-690693
    T6285937174-76-0
    GSK-690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. Phase 1.
    • $41
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • ML-9
    T16104105637-50-1
    ML-9 suppresses MLCK, PKA, and PKC activity with Ki values of 4, 32, and 54 μM, respectively. ML-9 is a selective and effective inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK), and stromal interaction molecule 1 (STIM1) activity. ML-9 causes autophagy by stimulating autophagosome formation and inhibiting their degradation.
    • $34
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Esculetin
    T2798305-01-1
    Esculetin (Cichorigenin) is a coumarin derivative from various natural plant products with various biological and pharmaceutical properties including anti-edema, anti-inflammatory and anti-tumour effects. It inhibits lipoxygenases (LOs).
    • $45
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Kazinol B
    T2023299624-27-8
    Kazinol B is an inhibitor of nitric oxide (NO) production, an isopentenylated flavan with a dimethylpyran ring.Kazinol B improves insulin sensitivity by activating the insulin-Akt signalling pathway and AMPK, which enhances glucose uptake.Kazinol B stimulates gene expression and secretion of adiponectin and can be used to study diabetes.
    • $1,760
    Backorder
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Desmethylanethol trithione
    T356018274-81-2
    Desmethylanethol trithione (ADT-OH) is a derivative of anethole dithiolethione (ADT) and synthetic hydrogen sulfide (H2S) donor. In the in vitro glucose-oxygen deprivation (OGD) model, Desmethylanethol trithione markedly attenuated tPA-enhanced Akt activation and VEGF expression in brain microvascular endothelial cells. Finally, Desmethylanethol trithione improved functional outcomes in mice subjected to MCAO and tPA infusion. H2S donors reduced tPA-induced cerebral hemorrhage by possibly inhibiting the Akt-VEGF-MMP9 cascade. Administration of H2S donors has potential as a novel modality to improve the safety of tPA following the stroke.
    • $41
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • MK-2206 free base
    T817841032349-93-1
    MK-2206 free base is an allosteric Akt inhibitor that is both potent and selective, administered orally, exhibiting IC50 values of 8, 12, and 65 nM for Akt1, Akt2, and Akt3, respectively. It demonstrates sensitivity in various breast cancer cell lines, including those with PIK3CA mutations and those exhibiting PTEN loss, indicating its potential for anticancer activities [1] [2].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Bakkenolide IIIa
    TN3486915289-60-0
    Bakkenolide IIIa has antioxidant, and neuroprotective effects, it protects against cerebral damage by inhibiting AKT and ERK1/2 activation and inactivated NF-κB signaling.
    • $740
    Backorder
    Size
    QTY
    TargetMol | Inhibitor Sale
  • 3,4,5-Tricaffeoylquinic acid
    TN123586632-03-3
    3,4,5-Tricaffeoylquinic acid may attenuate the TNF-α±- and LPS-stimulated production of inflammatory mediators in keratinocytes by suppressing the Toll-like receptor 4 expression-mediated activation of the Akt, ERK and NF-κB pathways, it may exert an inhibitory effect against the pro-inflammatory mediator-induced skin disease.
    • $2,508
    Backorder
    Size
    QTY
    TargetMol | Inhibitor Sale